Src Mutation Induces Acquired Lapatinib Resistance in ERBB2-Amplified Human Gastroesophageal Adenocarcinoma Models - Hong, Yong Sang; Kim, Jihun; Pectasides, Eirini; Fox, Cameron; Hong, Seung-Woo; Ma, Qiuping; Wong, Gabrielle S.; Peng, Shouyong; Stachler, Matthew D.; Thorner, Aaron R.; Van Hummelen, Paul; Bass, Adam J. (PloS one, 2014)
Keywords: 1-Phosphatidylinositol 3-kinase; Adenocarcinoma; Adenocarcinoma - drug therapy; Adenocarcinoma - genetics; Amplification; Antineoplastic Agents - pharmacology; Benzodioxoles - pharmacology; Biology and Life Sciences; Breast cancer; Cancer therapies; Cell culture; Cell cycle; Cell Line, Tumor; Chemotherapy; Clinical medicine; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm - genetics; Ectopic expression; Epidermal growth factor; ErbB-2 protein; Esophageal Neoplasms - drug therapy; Esophageal Neoplasms - genetics; Esophagus; Gene Amplification; Gene Expression; Gene Silencing; Genes, src; Genomes; Humans; Inhibition; Inhibitor drugs; Kinases; Medicine; Medicine and Health Sciences; Metastases; Metastasis; Mutation; Oncology; Pharmacology; Phosphorylation; Protein kinase; Protein Kinase Inhibitors - pharmacology; Quinazolines - pharmacology; Receptor, ErbB-2 - genetics; RNA Interference; Src protein; Stomach Neoplasms - drug therapy; Stomach Neoplasms - genetics; Targeted cancer therapy; Therapy; Tumors; United States--US; Massachusetts